Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on accelerated partial-breast irradiation.

Alphonse G Taghian1, Abram Recht

  • 1Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston MA 02114, USA. ataghian@partners.org

Current Oncology Reports
|February 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.

International journal of radiation oncology, biology, physics·2026
Same author

Omitting Radiation for Breast Cancer Patients Eligible for the NSABP B-51 Trial Who Achieve ypN0 After Neoadjuvant Chemotherapy.

Practical radiation oncology·2026
Same author

When Postmastectomy Radiotherapy (PMRT) is not Really PMRT: A Critical Evaluation of SUPREMO Trial.

Annals of surgical oncology·2026
Same author

Clinical Hypothyroidism After Proton Versus Photon Regional Nodal Irradiation: A Prospective Correlative Study Within the RADCOMP Randomized Trial.

International journal of radiation oncology, biology, physics·2026
Same author

Radiation Dose and Lymphedema Risk After Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection.

International journal of radiation oncology, biology, physics·2026
Same author

Analysis of factors associated with loco-regional failure in breast cancer patients following neoadjuvant chemotherapy.

Breast cancer research and treatment·2025
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Accelerated partial-breast irradiation (APBI) offers a precise, shorter treatment for early-stage breast cancer, potentially reducing side effects. This approach uses advanced radiotherapy techniques to target only the affected breast area.

Area of Science:

  • Radiation Oncology
  • Medical Physics
  • Oncology

Background:

  • Advancements in CT-guided simulation and 3D conformal planning enable precise radiation delivery.
  • Current radiotherapy can target localized breast areas, moving beyond whole-breast treatment.

Purpose of the Study:

  • To review the rationale behind accelerated partial-breast irradiation (APBI).
  • To outline the techniques used for performing APBI.
  • To summarize the current outcomes of APBI studies.

Main Methods:

  • Review of existing literature on accelerated partial-breast irradiation.
  • Analysis of radiotherapy techniques including brachytherapy and external-beam methods.
  • Evaluation of study outcomes for APBI in early-stage breast cancer patients.

Related Experiment Videos

Main Results:

  • APBI allows for precise targeting of the breast tumor area.
  • Potential for significantly shortened treatment courses for early-stage breast cancer.
  • Reduced toxicity to surrounding organs is a key potential benefit.

Conclusions:

  • Accelerated partial-breast irradiation is a viable option for select early-stage breast cancer patients.
  • Technological progress supports the safe and effective delivery of APBI.
  • Further outcome data will refine APBI's role in breast cancer treatment.